

# EUROPEAN NEUROPSYCHOPHARMACOLOGY

THE JOURNAL OF THE EUROPEAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY

ANALYZED

VOLUME 7, SUPPLEMENT 2 (1997)

**Abstracts of the  
Xth Congress of the European College of  
Neuropsychopharmacology**

Vienna, Austria  
September 13–17, 1997



ELSEVIER

VOLUME 7 (1997)

---

ELSEVIER SCIENCE B.V.

AMSTERDAM – LAUSANNE – NEW YORK – OXFORD – SHANNON – TOKYO

# EUROPEAN NEUROPSYCHOPHARMACOLOGY

The Journal of the European College of Neuropsychopharmacology

**Scope** *European Neuropsychopharmacology* provides a medium for the prompt publication of articles in the field of neuropsychopharmacology. Its scope encompasses clinical and basic research relevant to the effects of centrally acting agents in its broadest sense.

## Editors-in-Chief

J.M. van Ree (Utrecht, The Netherlands)

S.A. Montgomery (London, UK)

## Editorial Board

M. Ackenheil (Munich, Germany)  
C.M. Banki (Nagykallo, Hungary)  
P. Bech (Hillerød, Denmark)  
R.H. Belmaker (Beer Sheva, Israel)  
M. Bourin (Nantes, France)  
G.B. Cassano (Pisa, Italy)  
S.G. Dahl (Tromsø, Norway)  
C.G. Gottfries (Hisings Backa, Sweden)  
P. Grof (Ottawa, Ont., Canada)  
F. Holsboer (Munich, Germany)  
S.Z. Langer (Paris, France)  
M. Linnoila (Bethesda, MD, USA)  
J.J. López-Ibor (Madrid, Spain)  
J. Maj (Krakow, Poland)

P. McGuffin (Cardiff, UK)  
H.Y. Meltzer (Cleveland, OH, USA)  
J. Mendlewicz (Brussels, Belgium)  
T.R. Norman (Heidelberg, Vic., Australia)  
R. Post (Bethesda, MD, USA)  
G. Racagni (Milan, Italy)  
G. Sedvall (Stockholm, Sweden)  
S.H. Snyder (Baltimore, MD, USA)  
H.M. van Praag (Maastricht, The Netherlands)  
H.G.M. Westenberg (Utrecht, The Netherlands)  
P. Willner (London, UK)  
J.H. Woods (Ann Arbor, MI, USA)  
I. Yamashita (Sapporo, Japan)

**Types of paper** Full-length *Research Papers*: detailing findings of original experimental or clinical research in any area of neuropsychopharmacology; *Short Communications*: brief research reports or results that have reached a stage where they are ready for preliminary communication; *Reviews* on specialised topics. *Letters to the Editor* relating to material published in the journal are also welcomed.

**Submissions** *Non-clinical* manuscripts and related editorial correspondence should be addressed to: ENP Secretariat, P.O. Box 85410, 3508 AK Utrecht, The Netherlands.

*Clinical* manuscripts and related editorial correspondence should be addressed to: Professor Stuart A. Montgomery, European Neuropsychopharmacology, P.O. Box 8751, London W13 8WH, UK.

**Advertising information** Advertising orders and enquiries can be sent to:

*International*: Elsevier Science, Advertising Department, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, UK; Tel: +44 (0) 1865 843565; Fax: +44 (0) 1865 843976;

*USA and Canada*: Weston Media Associates, Dan Lipner, P.O. Box 1110, Greens Farms, CT 06436-1110, USA; Tel: +1 (203) 261 2500; Fax: +1 (203) 261 0101;

*Japan*: Elsevier Science Japan, Marketing Services, 1-9-15 Higashi-Azabu, Minato-ku, Tokyo 106, Japan; Tel: +81 3 5561 5033; Fax: +81 3 5561 5047.

**Publication information:** *European Neuropsychopharmacology* (ISSN 0924-977X). For [1997] volume 7 is scheduled for publication. Subscription prices are available upon request from the Publisher. Subscriptions are accepted on a prepaid basis only and are entered on a calendar year basis. Issues are sent by surface mail except to the following countries where Air delivery via SAL is ensured: Argentina, Australia, Brazil, Canada, Hong Kong, India, Israel, Japan, Malaysia, Mexico, New Zealand, Pakistan, PR China, Singapore, South Africa, South Korea, Taiwan, Thailand, USA. For all other countries airmail rates are available upon request. Claims for missing issues must be made within six months of our publication (mailing) date.

**Orders, claims, and product enquiries:** please contact the Customer Support Department at the Regional Sales Office nearest you:

### New York

Elsevier Science  
P.O. Box 945  
New York, NY 10159-0945  
USA  
Tel. (+1)212-633-3730  
[Toll free number for North  
American customers:  
1-888-4ES-INFO (437-4636)]  
Fax (+1)212-633-3680  
e-mail usinfo-f@elsevier.com

### Amsterdam

Elsevier Science  
P.O. Box 211  
1000 AE Amsterdam  
The Netherlands  
Tel. (+31)20-4853757  
Fax (+31)20-4853432  
e-mail nlinfo-f@elsevier.nl

### Tokyo

Elsevier Science  
9-15 Higashi-Azabu 1-chome  
Minato-ku, Tokyo 106  
Japan  
Tel. (+81)3-5561-5033  
Fax (+81)3-5561-5047  
e-mail kyf04035@niftyserve.or.jp

### Singapore

Elsevier Science  
No. 1 Temasek Avenue  
#17-01 Millenia Tower  
Singapore 039192  
Tel. (+65)434-3727  
Fax (+65)337-2230  
e-mail asiainfo@elsevier.com.sg

**Enquiries concerning manuscripts and proofs:** questions arising after acceptance of the manuscript, especially those relating to proofs, should be directed to: Elsevier Science Ireland Ltd, Bay 15, Shannon Industrial Estate, Shannon, Co. Clare, Ireland.

This journal and the individual contributions contained in it are protected by the copyright of Elsevier Science B.V., and the following terms and conditions apply to their use:

### Photocopying

Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

In the USA, users may clear permissions and make payment through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA. In the UK, users may clear permissions and make payment through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK, in other countries where a local copyright clearance centre exists, please contact it for information on required permissions and payments.

### Derivative Works

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution.

Permission of the Publisher is required for all other derivative works, including compilations and translations.

### Electronic Storage

Permission of the Publisher is required to store electronically any material contained in this journal, including any article or part of an article. Contact the Publisher at the address indicated.

*Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher.*

*No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, independent verification of diagnoses and drug dosages should be made.*

*Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.*

Periodicals postage paid at Rahway, New Jersey. *European Neuropsychopharmacology* (ISSN 0924-977X) is published in 4 issues per year, in March, June, September and December, by Elsevier Science Ireland Ltd., Bay 15, Shannon Industrial Estate, Shannon, Co. Clare, Ireland. The annual subscription in the USA is \$402.00. *European Neuropsychopharmacology* is distributed by Virgin Mailing and Distribution, 10 Camptown Road, Irvington, New Jersey 07111-1105. Postmaster: Please send address corrections to *European Neuropsychopharmacology*, c/o Elsevier Science Regional Sales Office, Customer Support Department, 655 Avenue of the Americas, New York, NY 10010.

☺ The paper used in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper).

Printed in The United Kingdom

**P.2.110 The German postmarketing surveillance of risperidone in daily practice: Gender differences with regard to demographic and treatment data**

M. Albus, M. Linden, A. Klauder, M. Philipp. *State Mental Hospital Haar, D 85540 Haar, Germany*

**Methods:** In the context of a German postmarketing surveillance on the long term use of risperidone in daily practice, gender differences with regard to demographic and treatment data during the first 3 months of risperidone administration investigated.

**Results:** 886 schizophrenic patients (452 males and 432 females) were included in the study. More males were single compared to females. Although females were older than males with a longer duration of illness, they showed a higher level of psychosocial functioning. During previous treatment females showed a higher rate of tardive dyskinesia, whereas male showed disturbed cognition more often. During treatment with risperidone the mean dosage of risperidone administered was lower in females, however significantly only after 1 month (4.9 mg vs 4.6 mg). The percentage of patients discontinuing treatment as well as medication compliance did not differ between the genders. Minus symptomatology was higher in men throughout the whole treatment period. Symptom improvement in plus and minus symptoms, in psychosocial functioning as well as in extrapyramidal side effects was significantly during the 3-month period, again without gender differences. As well, the therapeutic efficacy of risperidone was rated favorable in both groups.

**Conclusion:** Risperidone treatment during a 3-month-period was efficacious without differential effects on male and female schizophrenic patients.

**P.2.111 D<sub>2</sub> and 5 HT<sub>2A</sub> receptor binding of different doses of quetiapine in schizophrenics, a pet study**

O. Gefvert<sup>1</sup>, I.-M. Wieselgren<sup>2</sup>, P. Hagström<sup>1</sup>, M. Bergström<sup>3</sup>, T. Lundberg<sup>1</sup>, B. Långström<sup>3</sup>, F.A. Wiesel<sup>2</sup>, L.H. Lindström<sup>1</sup>.

<sup>1</sup>Psychiatric Research Unit Västerås; <sup>2</sup>Ulleråker Hospital, Uppsala; <sup>3</sup>Uppsala University PET centre, Sweden

Quetiapine ('Seroquel'), a dibenzothiazepine is a new anti-psychotic compound under development. In vitro data indicate that it has a similar receptor profile as that of clozapine, except for a much lower affinity for D<sub>4</sub> and muscarinic cholinergic receptors.

**Method:** We undertook a study in 5 schizophrenic patients. In 4 patients the dose of quetiapine was titrated up to 750 mg/day in one week. The dose was maintained for 21 days. At day 29 two PET scans were then performed two hours after dosing (at steady state) at 09.00 and 17.00. The ligand C<sup>11</sup>-raclopride was used to estimate D<sub>2</sub> receptor binding in the striatum, and C<sup>11</sup>-metylpiperone was used as ligand for 5 HT<sub>2A</sub> receptors in the frontal cortex. After the first two scans the dose of quetiapine was reduced to 450 mg/day and in 3 of these patients a further two PET scans were performed app. 8 days later at the steady state. The fourth patient had the dose of quetiapine further reduced to 300 mg/day before having two more PET scans. In the remaining patient, who was being well-controlled after titration to 450 mg/day, the dose was reduced to 300 mg/day and then to 150 mg/day with two PET scans at the last two levels at steady state...

**Results:**

Dose of quetiapine (mg)	150	300	450	750
Number of patients (n)	1	2	3	4
D <sub>2</sub> (% striatum)	0	0	31	43
5 HT <sub>2A</sub> (% frontal cortex)	38	57	74	76

**Discussion:** A consistent decrease of receptor blockade, on both D<sub>2</sub> and 5 HT<sub>2A</sub> receptors, could be demonstrated with decreasing doses of quetiapine.

The low values of D<sub>2</sub> blockade at 150 mg and 300 mg are consistent with the clinical findings of these patients deteriorating after dose reduction. They either had to discontinue quetiapine (n = 1) or increase the dose again to achieve symptom control (n = 1). However higher occupancy values can not be ruled out in other patients, at these dose levels, as the low number of patients in this study will not take into the account the possibility of an inter individual variation of D<sub>2</sub> occupancy.

These data confirm the findings of our earlier study that quetiapine binds to both D<sub>2</sub> and 5 HT<sub>2A</sub> receptors, but with a higher level of occupancy and with a much more withstanding blockade of the serotonin receptors. From these data it is unlikely that quetiapine will cause EPS in the recommended dose range (150–750 mg). Thereby fulfilling one criterion of being an atypical neuroleptic. The lack of EPS has been proposed to be related to a dopamine D<sub>2</sub> occupancy of less than 75% and at the maximum recommended dose (750 mg) is well below this level.

This study has been sponsored by Zeneca Pharmaceuticals, England. 'Seroquel' is a trade mark and the property of Zeneca Ltd.

**P.2.114 Aripiprazole, a new typical antipsychotic: Phase 2 clinical trial result**

J.L. Petrie<sup>1</sup>, A.R. Saha<sup>1</sup>, J.P. McEvoy<sup>2</sup>. <sup>1</sup>Otsuka America Pharmaceuticals, CNS Research, Rockville, Maryland, USA, <sup>2</sup>John Umstead Hospital, Duke University, Butner, NC 27509, USA

Aripiprazole is a new atypical antipsychotic now starting world wide Phase III development by Otsuka Pharmaceuticals. Receptor pharmacology showed that aripiprazole is a postsynaptic dopamine receptor antagonist as well as presynaptic autoreceptor agonist. The latter action distinguishes aripiprazole from other currently available antipsychotic drugs. Aripiprazole also demonstrated affinity for 5HT<sub>2</sub> receptor. Aripiprazole has a T-max of 3–5 hr with a half life of 50–80 hr. A positron emission tomography (PET) study showed that aripiprazole enters the brain and its binding to the D<sub>2</sub> receptor increases with increasing doses.

Recently completed double-blind Phase II studies were conducted in a total of 410 acutely relapsing hospitalised schizophrenic patients. In study 31-93-202, aripiprazole was titrated up from 5 to 30 mg in 13 days while in study 31-94-202 fixed doses of 2, 10, and 30 mg/day were administered. Both studies were of 4 weeks duration, and haloperidol was used as an active control.

Based on the last observation carried forward (LOCF) analysis, in both studies aripiprazole was superior to placebo in improving the BPRS-total, BPRS-score, CGI-severity, and PANSS-total. Results of the fixed-dose study of 31-94-202 showed that all three aripiprazole doses (2, 10, and 30 mg/day) showed clinical effect in improving the symptoms of acute psychiatric exacerbation of schizophrenia and the 30 mg dose was consistently more effective than the lower two doses. The 30 mg dose demonstrated a unique early onset of efficacy from week 1 on all efficacy variables including PANSS-negative score.

Aripiprazole was well tolerated. Extrapyramidal symptoms (EPS) as measured by standard scales were comparable to the placebo treatment. In the aripiprazole treatment groups there was no increase in prolactin level or in body weight.

A favorable safety profile combined with data supporting efficacy in the treatment of the positive and negative symptoms of schizophrenia, suggests that aripiprazole may represent an important advance in the management of psychotic disorders.

**P.2.115 Depressive symptoms in acute schizophrenia: Evaluation and outcome under new antipsychotics**

M.J. Müller, O. Benkert. *Department of Psychiatry, University of Mainz, Germany*

Depressive symptoms occur frequently during the course of psychotic disorders. Despite of their high clinical relevance, there is so far no commonly accepted guideline for evaluation and treatment of depressive symptomatology in more acute states of these disorders. However, recent studies with novel antipsychotics seem to yield promising results. Due to the complex nature of psychotic disorders, a substantial overlap of depressive and negative symptoms and the possible confounding with positive symptomatology and treatment-induced extrapyramidal side-effects (EPS) may account for difficulties in discriminating treatment outcome with respect to depressive symptoms.

Based on recent factor-analytical models of schizophrenic symptomatology, the present approach focused on depressive symptoms. Using confirmatory factor analysis (CFA, LISREL 7.20), a baseline model